CLAIMS

1. Use of a TNF Receptor in combination with a steroid hormone to produce a pharmaceutical composition for the treatment of lethal bacterial and viral infections.
2. Use of a TNF Receptor in combination with a steroid hormone to produce a pharmaceutical composition for the treatment of autoimmune and inflammatory diseases.
3. The use according to Claim 1 or 2, wherein the TNF Receptor and the steroid hormone are used simultaneously, separately or sequentially.
4. The use according to any preceding claim, wherein the TNF Receptor is selected between the extracellular soluble domain of TNF-R1, TBP-1 and the extracellular soluble domain of TNF-R2, TBP-2.
5. The use according to any preceding claim, wherein the TNF Receptor is the extracellular soluble domain of TNF-R1, TBP-1.
6. The use according to any preceding claim, wherein the steroid hormone is selected between a corticosteroid and an androgen.
7. The use according to claim 6, wherein the steroid hormone is an androgen.
8. The use according to claims 6 or 7, wherein the androgen is DHEA.
9. The use according to claim 1, wherein the lethal bacterial infection is septic shock.
10. Pharmaceutical composition containing a TNF receptor and a steroid hormone, in the presence of one or more pharmaceutically acceptable excipients, for the simultaneous, separate or sequential use of its active ingredients in the treatment of lethal bacterial and viral infections.
11. Pharmaceutical composition containing a TNF receptor and a steroid hormone, in the presence of one or more pharmaceutically acceptable excipients, for the simultaneous, separate or sequential use of its active ingredients in the treatment of autoimmune and inflammatory diseases.
12. The pharmaceutical composition according to claim 10 or 11, wherein the TNF Receptor is selected between the extracellular soluble domain of TNF-R1, TBP-1 and the extracellular soluble domain of TNF-R2, TBP-2.
13. The pharmaceutical composition according to claims 10 or 12, wherein the TNF Receptor is the extracellular soluble domain of TNF-R1, TBP-1.

14. The pharmaceutical composition according to any of claims 10 to 13, wherein the steroid hormone is selected between a corticosteroid and an androgen.
15. The pharmaceutical composition according to any of claims 10 to 14, wherein the steroid hormone is an androgen.
16. The pharmaceutical composition according to any of claims 10 to 15, wherein the androgen is DHEA.
17. The pharmaceutical composition according to claim 10, wherein the lethal baterial infection is septic shock.

add A2